↑ トップへ　← 戻る

66. IgA腎症
［臨床試験数：199，薬物数：214（DrugBank：57），標的遺伝子数：32，標的パスウェイ数：128］

Searched query = "IgA nephropathy", "IgA nephritis", "Berger disease", "IgA-IgG nephropathy"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
6 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT02231125
(ClinicalTrials.gov)		September 201430/8/2014Efficacy and Safety of Abelmoschus Manihot for IgA NephropathyEfficacy and Safety of Abelmoschus Manihot for IgA Nephropathy: a Multicentre, Double-blind, Double-dummy, Randomized Controlled TrialIgA NephropathyDrug: Losartan;Drug: Abelmoschus manihotChen XiangmeiJiangsu Suzhong Pharmaceutical Group Co., Ltd.Recruiting18 Years65 YearsBoth1600Phase 4China
2NCT01854814
(ClinicalTrials.gov)		July 20139/5/2013The Effects of Mycophenolate Mofetil (MMF) on Renal Outcomes in Advanced Immunoglobulin A (IgA) Nephropathy PatientsThe Effects of Mycophenolate Mofetil on Renal Outcomes in Patients With Advanced IgA Nephropathy: a Randomized Open-label StudyIgA NephropathyDrug: Mycophenolate mofetil;Drug: LosartanFan Fan HouNULLRecruiting16 Years70 YearsAll232N/AChina
3JPRN-UMIN000002887
2009/12/0114/12/2009A multicenter study to examine renal protection by a combination of an HMG-CoA reductase inhibitor and losartan in patients with dyslipidemia associated with IgA nephropathy IgA nephropathystatin and losartan group:
simvastatin 5mg and Losartan 50mg/day more than 3 months
statin group:
simvastatin 5mg/day more than 3 months		Fukuoka University Faculty of MedicineNULLRecruiting20years-oldNot applicableMale and Female80Not selectedJapan
4NCT00922311
(ClinicalTrials.gov)		July 200914/6/2009Aliskiren for Proteinuric IgAN Despite Angiotensin BlockadeAliskiren Combined With Losartan in Immunoglobulin A Nephropathy: an Open-label Pilot StudyIgA NephropathyDrug: AliskirenThe University of Hong KongQueen Mary Hospital, Hong Kong;United Christian HospitalCompleted18 Years70 YearsBoth25Phase 4China
5ChiCTR-TRC-06000004
2006-01-012006-09-14ACEi/ARB alone versus ACEi/ARB plus Steroids in the treatment of primary IgA nephropathy, a randomized multicenter controlled trialACEi/ARB alone versus ACEi/ARB plus Steroids in the treatment of primary IgA nephropathy, a randomized multicenter controlled trial primary IgA nephropathygroup 1:treated with ACEI/ARB( ARB therapy is subjected to patients with cough after use of ACEI) Inhibace (cilazapril): start at 1.25mg/day, increase the dose by 1.25mg/day/week to 2.5-5mg/day Cozaar (losartan): 25~50mg/day, increased to 50~100mg/day Last for one year;group 2:Oral prednisone for 6 mos 0.8mg/kg/day x 8 wks Tapered 0.2mg/kg/day/mo in combination with ACEI/ARB;The First Hospital, Peking UniversityNULLCompleted1665Bothgroup 1:78;group 2:78;China
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
6JPRN-C000000006
2005/01/0101/08/2005Lisinopril only and a combination of lisinopril and losartan for IgA nephropathy with focal mesangial proliferation in children: A randomized controlled trial of efficacy and safety IgA nephropathy in childrenLisinopril for 2 years
Lisinopril+losartan for 2 years		Japanese Study group of Kidney Disease in ChildrenNULLComplete: follow-up complete2years-old18years-oldMale and Female110Not selectedJapan

先頭へ